advances are technologies that assay a rare population of tumor cells shed into circulation (2)-called circulating tumor cells, or CTCs-from primary and metastatic tumor sites that may both contribute to the development of metastatic disease and ref ect the heterogeneity that likely exists between various tumor deposits (Fig. 1 ). T ese rare cells have been approximated to average 1 CTC for every 1 billion peripheral blood cells, emphasizing the challenges in their isolation and analysis. CTCs have been collected with the goal of understanding their role in the metastatic cascade and, ultimately, to predict patient outcomes from both the disease as well as treatments for that disease (3) . In this issue of Science Translational Medicine, Issadore and colleagues describe an innovative microf uidic assay with high sensitivity and specif city to detect CTCs expressing multiple cell-surface markers (4) . To achieve this goal, the authors designed a microf uidic device using microHall (µHall) sensors to detect the magnetic moment from immunolabeled cells bound with magnetic nanoparticles (4) . By varying the size of the nanoparticles, the µHall detector (µHD) was able to sensitively identify and quantify dif erent cell-surface proteins recognized by each particle. A series of validation experiments showed excellent specif city and superior sensitivity to enumerate more CTCs from the peripheral blood of 20 patients with ovarian cancer compared to the commercially available CellSearch assay (Veridex): A median of 1 CTC per 7.5 ml of blood was recovered with CellSearch, versus 57 per the same volume of blood with the µHD.
Issadore et al. further extended this technology to assay for expression of cell-surface markers that are relevant for detection and may be therapeutic targets in other solid-tumor malignancies (4)-for instance, human epidermal growth factor receptor 2 (HER2/ neu) in breast and ovarian cancers and epidermal growth factor receptor (EGFR) in lung cancer. In this series of experiments, the authors implanted a human epidermoid cancer cell line into a mouse model and then initiated systemic therapy with an HSP90 inhibitor (geldenamycin) known to alter EGFR expression. Using the µHD, they were able to detect alterations in EGFR expression from tumor aspirates during treatment. T ese preclinical studies with the µHD suggest that this approach may have adequate sensitivity to detect alterations in cell-surface targets of new molecular therapies, such as EGFR, during a patient's course of treatment.
Extensive studies on the mechanisms by which metastases develop suggest that heterogeneity exists among tumor deposits, and subsets of these cells have greater metastatic potential (5). T is heterogeneity can extend from genomic, proteomic, and functional dif erences among these cell populations. Subpopulations of CTCs may have greater potential to extravasate into circulation from a tumor and seed a metastatic site, whereas cells that disseminate by means other than circulation, such as aggressive local invasion or lymph node metastases, may be another subpopulation of cells within the tumor milieu. Given these hypotheses, the isolation and evaluation of CTCs will be crucial to understanding the mechanisms by which secondary metastatic sites form.
T e enumeration of bulk CTCs from patients with advanced cancer has yet to answer whether these isolated cells are responsible for the initiation of a metastatic site, are cells in-transit from already established metastatic sites, or are merely sloughed cell populations with little relevance for the cancer progression or responses to anticancer therapies (Fig. 1) . Devices such as that described by Issadore et al. (4) extend the potential of CTC analysis to subpopulations of CTCs and further interrogation of these cells in the process of patient care. However, translation of these technologies into patient benef t requires extensive knowledge of the strengths and limitations of each assay with a particular prognostic or predictive goal in mind-thus, "knowing yourself " to f t within the conceptual frameworks of Sun Tzu and, more importantly, regulatory bodies, which approve such devices for human use.
TECHNOLOGIES FOR ISOLATING CTCS
Over the past 15 years, various technologies have been developed to permit the isolation and analysis of CTCs (6) (7) (8) and can generally be divided into positive and negative selection methodologies. Positive selection techniques to isolate cells are based on expression of cell-surface markers, such as the epithelial cell adhesion molecule (Ep-CAM), and include the CellSearch assay, the Herringbone-CTC chip (9) , and f ow cytometry-based approaches ( Fig. 1) (3) . T e CellSearch assay is U.S. Food and Drug Administration (FDA)-approved and def nes CTCs as those events that are EpCAMpositive, negative for a lymphocyte marker (CD45), positive for a nuclear stain (DAPI), and positive for cytokeratins 8 and 18. However, positive selection technologies are criticized for their reliance on cell-surface expression of EpCAM to capture (and def ne)
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CTCs because some tumors down-regulate expression of this marker during epithelialmesenchymal transitions (EMTs), whereas other tumor types, such as renal cell carcinoma, do not commonly express EpCAM.
To address this limitation, negative selection technologies are being developed that isolate CTCs on the basis of physicochemical properties-such as size, density, or surface charges-that distinguish them from other blood cells (10-12). Issadore et al. took a dif erent approach by assaying for multiple cell-surface markers with their µHD (4). Using multiple markers provided specif city similar to f ow-based approaches while minimizing cell manipulation.
Various technologies are now identifying both concordant and discordant results with regards to enumeration of CTCs that remind us of the fundamental questions regarding the biology of these cells and how they should be def ned in the context of cancer. For example, Armstrong et al.
proposed that a subset of EpCAM-positive CTCs expressing CD133 has greater invasive potential and may be a more relevant population to isolate and study (13) . Is it possible that this population of cells may hold greater prognostic import than cells that do not express these markers? According to some recent reports, some CTCs may also lack surface expression of EpCAM and would likely be missed by the CellSearch and other positive-selection assays (14) . In this case, these technologies would be underreporting CTC burden in patients with metastatic cancers.
Can we gain greater information density on the underlying genomic and proteomic heterogeneity among these rare cells? Danila et al. found that CTCs from patients with prostate cancer can be analyzed for expression of cancer-specif c genes, including androgen receptor (AR) and the gene fusion TMPRSS2-ERG (15). Magbanua and colleagues identif ed dif erent amplif cation events in AR in CTCs from patients with prostate cancer and from archival patient samples (16) . T ese inter-and intrapatient variations suggest a greater underlying complexity in CTCs, including heterogeneous subpopulations and progressive genomic aberrations typical in later-stage/metastatic disease.
As of en occurs with advances in medicine, greater underlying complexity can inhibit or impede the translation of these advances into therapeutic benef t for our patients. T is complexity can also impede the broad adoption of new technologies if they are unable to either account for or predict individual patient responses and outcomes. T e degree to which these current technologies can answer these critical questions is unclear, and validation studies are ongoing. Issadore et al. reported detection of CTCs from patients with various histologic subtypes of ovarian cancer, with either stage III or IV disease (4), that had not previously been identif ed. Furthermore, the authors also identifed higher CTC burdens from patients with cancers with platinum chemotherapy-resistant disease versus platinum chemotherapy-sensitive disease. T ese results raise critical questions as to whether the presence of these previously unidentif ed cells is relevant for recurrent cancers or patient outcomes. Ultimately, whether these cells will further our understanding of the progression of ovarian cancer is unknown, but their identif cation is the f rst step in developing a new cell-based biomarker.
CTCS AS BIOMARKERS?
Ultimately, the great hope in the continued investigation of CTCs is the development of an easily accessible biomarker (in blood, for example) that could be repeatedly interrogated to inform physicians on an individual's tumor biology, predict which therapeutic interventions may be of greatest benef t, monitor treatment responses to therapy, and/or assay for mechanisms of therapeutic resistance to guide subsequent therapies (Fig. 2) . T e potential simplicity by which CTCs could be repeatedly assessed for these purposes would (17) . Yet, no current CTC-based assay has been shown to have a predictive capacity to drive therapeutic decision-making, although numerous research ef orts are under way.
Aspects of heterogeneity
CTCs may also be useful for drug development. For these purposes, a biomarker can be qualif ed as either a pharmacodynamic marker that can be assayed for a specif c molecular target or drug ef ect versus a surrogate marker, in which alterations of the marker correlate with a clinical end point that would suggest patient benef t from a particular therapy. T e emphasis from the National Cancer Institute/Cancer T erapy Evaluation Program for the concordant development of companion biomarkers with novel therapeutic agents further supports the development of CTC assays as alternative pharmacodynamic biomarkers in early-phase drug development (18) . T e preclinical studies performed by Issadore et al. suggest that the µHD may have the sensitivity to track changes in EGFR expression on CTCs af er treatment with an HSP90 inhibitor that promotes degradation of this cellsurface marker; thus, CTCs could act as a potential biomarker to monitor drug ef ects.
Nevertheless, the ability of a CTC assay to act as a surrogate biomarker for a clinical end point is a much higher bar to achieve than as a prognostic marker. A report from Scher and colleagues showed that alterations in CTC number, as assessed by the CellSearch assay, correlated with overall survival in a randomized phase III trial testing of abiraterone acetate versus placebo in patients with metastatic prostate cancer (19) . T i s study conf rmed the ability to use CTC enumeration as a surrogate marker for overall survival. If this result is conf rmed in other phase III trials with this patient population, it may be possible to use CTCs as alternative indicators of therapeutic ef cacy without having to wait for overall survival as an end point for drug approval, thus speeding the evaluation of new therapeutic agents.
It is clear that there are several potential uses for CTCs as biomarkers. It is important to recognize that each application will require its own series of validation studies, as mandated by the FDA for all biomarker development as well as for the widespread adoption of a new technology in clinical practice (20) . Brief y, the f rst benchmarks that a CTC biomarker must meet are experimental validation of the sensitivity, specif city, range of detection, and reproducibility of the assay along with initial clinical data and comparisons with existing CTC assays (21). Issadore and colleagues have met the initial validation benchmarks for this technology, including the sensitivity, specif city, and range of detection of CTCs based on four cell-surface markers for patients with ovarian cancer. Further validation experiments will depend on the authors' development strategy for this technology as a prognostic, predictive, and/or pharmacodynamic biomarker, as well as whether this assay will be developed to assay CTCs from other tumor types.
With both successful validation experiments and a development strategy in hand, qualif cation studies are then pursued to use the assay under development in Clinical Laboratory Improvement Amendments (CLIA)-certif ed laboratories. Other than def ned specimen acquisition, handling, processing, and storage requirements, the device described by Issadore et al. (4) would need to be replicated in multiple, independent laboratories, including appropriate quality controls and potential sources of assay failure. Such independent validation would also lead to def ned standards for data analysis, interpretation, and reporting. T e next major hurdle involves large-scale fabrication, training, and dissemination of this technology to a core set of CLIA-certif ed laboratories to process samples from clinical trials. With these steps in place, a new CTC assay will move forward into large-scale clinical trials.
OTHER CONSIDERATIONS ON THE ROAD TO THE CLINIC
With these standards and validation studies in place, an assay can be moved into product development with the appropriate experimental and therapeutic niche in mind. However, cost issues must be taken into account at each step in assay development. To reach qualif cation studies, the initial investments to develop the assay include device fabrication, automation (if neces- This schematic suggests how an integrated CTC biomarker could be used in a comprehensive approach to individualize patient care. Such a biomarker could provide prognostic information on a patient's disease burden; interrogate the biology and heterogeneity of this disease, including potential subpopulations that may exhibit potential resistance mechanisms; direct therapies to those with the greatest potential to act; and last, monitor treatment responses to continue treatment or stop an ineff ective therapy as resistant clones emerge. (22) . T e costs associated with these are substantial and limiting without broad support from grant agencies and/or private investors. However, the potential cost savings to the health care system can be as important if patients can be stratif ed to receive or avoid expensive therapies on the basis of these biomarkers. In summary, experimental validation of the strengths and limitations of a CTC assay has the potential to inform not only our understanding of a patient's disease but also their response to therapies. Reinterrogation of these cells at earlier time points in a treatment course could then inform us of the potential (or lack of) benef t of a given therapy and enable earlier decision-making to stop an inef ective therapy and move on to alternative choices. T is is becoming a key issue as newer agents continue to be approved in multiple tumor types and as cancer resistance to therapeutics increases. We can now begin to imagine a clinical encounter in which continual disease reassessment can truly personalize therapy for patients with advanced cancer, including drug choice, duration of therapy, and quality of life (Fig. 2) . Only af er such evidence is in place will widespread adoption of a new technology be undertaken to transform the care and lives of patients with cancer. Advancing the µHD presented in this issue of Science Translational Medicine into validation studies and clinical use will require dedicated ef ort, but the reward is improved care and outcomes for patients.
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